Syndax Pharmaceuticals Depreciation And Amortization Over Time

SNDX Stock  USD 14.29  0.19  1.31%   
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Syndax Pharmaceuticals Performance and Syndax Pharmaceuticals Correlation.
For more information on how to buy Syndax Stock please use our How to Invest in Syndax Pharmaceuticals guide.
  
Depreciation And Amortization is likely to drop to about 13.1 K in 2025.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Syndax Pharmaceuticals. If investors know Syndax will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Syndax Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.72)
Revenue Per Share
0.277
Quarterly Revenue Growth
332.974
Return On Assets
(0.32)
Return On Equity
(0.76)
The market value of Syndax Pharmaceuticals is measured differently than its book value, which is the value of Syndax that is recorded on the company's balance sheet. Investors also form their own opinion of Syndax Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Syndax Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Syndax Pharmaceuticals' market value can be influenced by many factors that don't directly affect Syndax Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Syndax Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Syndax Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Syndax Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Specify up to 10 symbols:

Cross Equities Depreciation And Amortization Analysis

Compare Syndax Pharmaceuticals and related stocks such as Cogent Biosciences, Cullinan Oncology LLC, and Kalvista Pharmaceuticals Depreciation And Amortization Over Time
Select Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Shareholders Equity Per ShareDebt To Equity
Capex Per ShareGraham Net Net
Average ReceivablesRevenue Per Share
Interest Debt Per ShareDebt To Assets
Enterprise Value Over E B I T D AGraham Number
Short Term Coverage RatiosPrice Earnings Ratio
Operating CyclePrice Book Value Ratio
Price Earnings To Growth RatioDays Of Payables Outstanding
Dividend Payout RatioPrice To Operating Cash Flows Ratio
Price To Free Cash Flows RatioPretax Profit Margin
Ebt Per EbitOperating Profit Margin
Effective Tax RateCompany Equity Multiplier
Long Term Debt To CapitalizationTotal Debt To Capitalization
Return On Capital EmployedDebt Equity Ratio
Ebit Per RevenueQuick Ratio
Dividend Paid And Capex Coverage RatioNet Income Per E B T
Cash RatioCash Conversion Cycle
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Fixed Asset TurnoverCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On Equity
2010201120122013201420152016201720182019202020212022202320242025
COGT179 K179 K179 K179 K179 K179 K830 K1.2 M1.3 M1.3 M720 K147 K5.9 M2.3 M2.6 M1.7 M
CGEM43 K43 K43 K43 K43 K43 K43 K43 K43 K70 K62 K53 K93 K310 K356.5 K374.3 K
KALV38 K38 K38 K27 K38 K33 K40 K180 K378 K879 K651 K743 K802 K816 K938.4 K985.3 K
MRSN297 K297 K297 K297 K297 K297 K655 K928 K1.3 M1.2 MM855 K927 K1.5 M1.7 M1.1 M
PLRX666 K666 K666 K666 K666 K666 K666 K666 K666 K1.1 M1.3 M1.5 M3.7 M1.8 M2.1 M1.9 M
RVMD1.2 M1.2 M1.2 M1.2 M1.2 M1.2 M1.2 M1.2 M1.8 M5.5 M6.5 M7.3 M9.7 M9.3 M10.7 M6.5 M
VRDN144.3 K144.3 K144.3 K148.3 K144 K184 K189 K308 K281 K941 K539 K620 K755 K522 K600.3 K437.8 K
INZY26 K26 K26 K26 K26 K26 K26 K26 K26 K83 K217 K1.1 M744 K833 K958 K541.8 K
AVTE1000100010001000100010001000100010001000100015 K68 K96 K110.4 K115.9 K
KROS304 K304 K304 K304 K304 K304 K304 K304 K304 K438 K605 K898 K1.6 M815 K1.2 M927.8 K
MLYS2.9 M2.9 M2.9 M2.9 M2.9 M2.9 M2.9 M2.9 M2.9 M2.9 M2.9 M18.7 M228.5 K167.9 K151.1 K143.6 K
REPL122 K122 K122 K122 K122 K122 K122 K109 K148 K533 K4.1 M4.6 M2.4 M2.7 M3.1 MM
PCVXMMMMMMMMM5.3 M1.4 M1.8 M9.2 M3.2 M3.6 MM
LRMR70 K70 K70 K70 K70 K70 K212 K188 K261 K78 K155 K326 K318 K311 K357.6 K234.5 K
MRUS364.6 K364.6 K364.6 K364.6 K307.7 K211 K246.1 K381.5 K729.8 K(1.6 M)1.4 M1.5 M1.3 M2.5 M2.5 M2.6 M
STRO5.7 M5.7 M5.7 M5.7 M5.7 M5.7 M5.7 MM4.5 M8.9 M4.3 M9.8 M8.3 M6.8 M7.8 M7.3 M
CYTK2.8 M1.3 M591 K433 K490 K589 K741 K1.9 M1.2 M5.8 M1.8 M9.6 M8.4 M11.9 M9.5 M10 M
EWTX123 K123 K123 K123 K123 K123 K123 K123 K123 K123 K185 K272 K538 K1.7 MM2.1 M
DYN333 M346 M26 M467 M292 M614 M766 M867 M24 K(762 K)700 K1.1 M1.7 M2.5 M2.2 M2.1 M

Syndax Pharmaceuticals and related stocks such as Cogent Biosciences, Cullinan Oncology LLC, and Kalvista Pharmaceuticals Depreciation And Amortization description

The systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives.

My Equities

My Current Equities and Potential Positions

Syndax Pharmaceuticals
SNDX
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
LocationMassachusetts; U.S.A
ExchangeNASDAQ Exchange
USD 14.29

Additional Tools for Syndax Stock Analysis

When running Syndax Pharmaceuticals' price analysis, check to measure Syndax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syndax Pharmaceuticals is operating at the current time. Most of Syndax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syndax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syndax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syndax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.